Literature DB >> 19595902

Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia.

Christopher M Clark1, Domenico Pratico, Lesley M Shaw, Susan Leight, Sharon X Xie, Amy Gu, Virginia M-Y Lee, John Q Trojanowski.   

Abstract

Entities:  

Year:  2006        PMID： 19595902      PMCID： PMC2712892          DOI： 10.1016/j.jalz.2006.05.2347

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN： 1552-5260            Impact factor:   21.566


× No keyword cloud information.
  27 in total

Review 1.  Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

Authors:  Richard A Frank; Douglas Galasko; Harald Hampel; John Hardy; Mony J de Leon; Pankaj D Mehta; Joseph Rogers; Eric Siemers; John Q Trojanowski
Journal:  Neurobiol Aging       Date:  2003 Jul-Aug       Impact factor: 4.673

2.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

Review 3.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

4.  Oxidative damage is the earliest event in Alzheimer disease.

Authors:  A Nunomura; G Perry; G Aliev; K Hirai; A Takeda; E K Balraj; P K Jones; H Ghanbari; T Wataya; S Shimohama; S Chiba; C S Atwood; R B Petersen; M A Smith
Journal:  J Neuropathol Exp Neurol       Date:  2001-08       Impact factor: 3.685

5.  Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity.

Authors:  D Praticò; C M Clark; V M Lee; J Q Trojanowski; J Rokach; G A FitzGerald
Journal:  Ann Neurol       Date:  2000-11       Impact factor: 10.422

6.  Frontotemporal dementia: clinicopathological correlations.

Authors:  Mark S Forman; Jennifer Farmer; Julene K Johnson; Christopher M Clark; Steven E Arnold; H Branch Coslett; Anjan Chatterjee; Howard I Hurtig; Jason H Karlawish; Howard J Rosen; Vivianna Van Deerlin; Virginia M-Y Lee; Bruce L Miller; John Q Trojanowski; Murray Grossman
Journal:  Ann Neurol       Date:  2006-06       Impact factor: 10.422

7.  Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Authors:  Niels Andreasen; Eugeen Vanmechelen; Hugo Vanderstichele; Pia Davidsson; Kaj Blennow
Journal:  Acta Neurol Scand Suppl       Date:  2003

8.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Authors:  D Galasko; L Chang; R Motter; C M Clark; J Kaye; D Knopman; R Thomas; D Kholodenko; D Schenk; I Lieberburg; B Miller; R Green; R Basherad; L Kertiles; M A Boss; P Seubert
Journal:  Arch Neurol       Date:  1998-07

Review 9.  Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases.

Authors:  Kathleen S Montine; Joseph F Quinn; Jing Zhang; Joshua P Fessel; L Jackson Roberts; Jason D Morrow; Thomas J Montine
Journal:  Chem Phys Lipids       Date:  2004-03       Impact factor: 3.329

10.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Authors:  K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910
View more
  6 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 3.  Biomarkers for early detection of Alzheimer pathology.

Authors:  C M Clark; C Davatzikos; A Borthakur; A Newberg; S Leight; V M-Y Lee; J Q Trojanowski
Journal:  Neurosignals       Date:  2007-12-05

Review 4.  Biomarker discovery in neurodegenerative diseases: a proteomic approach.

Authors:  Min Shi; W Michael Caudle; Jing Zhang
Journal:  Neurobiol Dis       Date:  2008-09-26       Impact factor: 5.996

5.  Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry.

Authors:  Magdalena Korecka; Teresa Waligorska; Michal Figurski; Jon B Toledo; Steven E Arnold; Murray Grossman; John Q Trojanowski; Leslie M Shaw
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.

Authors:  N Schuff; N Woerner; L Boreta; T Kornfield; L M Shaw; J Q Trojanowski; P M Thompson; C R Jack; M W Weiner
Journal:  Brain       Date:  2009-02-27       Impact factor: 13.501
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.